Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer.

Oncotarget 2015 May 30

filter terms:

Although normally restricted to activated T and B cells and mature dendritic cells, constitutive expression of CD70, a member of the tumor necrosis family, has been described in both hematological and solid tumors, where it increases tumor cell and regulatory T cell survival by signaling through its receptor, CD27.We have assessed the co-expression of CD70 and CD27 in non-small cell lung cancer (NSCLC) by immunohistochemistry to explore a correlation between expression of the protein and tumor histologic subtype, genetic aberrations and prognosis. Furthermore, we tested the ability of ARGX-110, a CD70-blocking antibody, to induce NK cell-mediated cytotoxicity.Our results revealed CD70 expression on the surface of both primary and metastatic NSCLC tumor cells and in the tumor microenvironment. Moreover, CD27-expressing tumor infiltrating lymphocytes were found adjacent to the tumor cells, suggesting active CD70-mediated signaling. Finally, we have shown that ARGX-110, has potent cytotoxic effects on CD70+ NSCLC cell lines.

Citation

Julie Jacobs, Karen Zwaenepoel, Christian Rolfo, Jolien Van den Bossche, Christophe Deben, Karen Silence, Christophe Hermans, Evelien Smits, Paul Van Schil, Filip Lardon, Vanessa Deschoolmeester, Patrick Pauwels. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget. 2015 May 30;6(15):13462-75